Prabhat Ayurvedic Pharmacy
Start Your Product

Herb library · Updated 16 October 2026 · By Aashish Passi · 25 sources

Triphala: what the research says

Triphala ('three fruits') is a classical Ayurvedic powder made of equal parts of the dried fruit rind of Haritaki (Terminalia chebula), Bibhitaki (Terminalia bellirica) and Amalaki (Phyllanthus emblica); the Ayurvedic Formulary of India lists it as Triphala Churna, citing the Bhavaprakasha. It is one of the most widely used Ayurvedic preparations, traditionally used for bowel regularity and as a rasayana (rejuvenative), and Health Canada permits it as a traditional mild laxative for occasional constipation. The fruits are rich in tannins and phenolic acids such as gallic, chebulagic and chebulinic acid. Human research is strongest for Triphala used as a mouthrinse for plaque and gingivitis; oral use for constipation, cholesterol or blood sugar rests on small or methodologically limited trials.[1, 6, 7, 9, 19, 25]

At a glance

Names and identity

Common nameTriphala (Triphala Churna)
SanskritTriphalā (त्रिफला); Triphalā Cūrṇa
Hindiत्रिफला (Triphala)
Punjabiਤ੍ਰਿਫਲਾ (Triphala)
Botanical namePolyherbal formulation, equal parts of fruit pericarp of: Terminalia chebula Retz. (Haritaki); Terminalia bellirica Roxb. [API spelling: T. belerica Roxb.] (Bibhitaki); Phyllanthus emblica L. [API: Emblica officinalis Gaertn., syn. Phyllanthus emblica Linn.] (Amalaki)
FamilyCombretaceae (Terminalia chebula, T. bellirica); Euphorbiaceae as placed in API (Emblica officinalis / Phyllanthus emblica)
Part usedPericarp of dried mature/ripe fruits of all three species, seed removed (API Part I Vol I monographs 4, 17, 31; AFI 7:15 specifies pericarp, 'P.')
Sanskrit synonymsVarā (used for Triphala in AFI Part I ingredient lists, e.g. 'Vara (triphala) kvatha'), Component synonyms per AFI/API: Pathyā / Abhayā (Haritaki); Bibhīta / Vibhīta / Akṣa (Bibhitaki); Dhātrī / Āmalaka / Amṛtaphala (Amalaki)

Ayurveda

Triphala in the Ayurvedic Pharmacopoeia

Rasa (taste)Not stated for the formulation in AFI. Components per API: Haritaki – Kashaya, Katu, Tikta, Amla, Madhura; Bibhitaki – Kashaya; Amalaki – Amla, Kashaya, Madhura, Tikta, Katu
Guna (qualities)All three components: Laghu, Ruksha (API)
Virya (potency)Haritaki – Ushna; Bibhitaki – Ushna; Amalaki – Shita (API)
Vipaka (post-digestive effect)Madhura for all three components (API)
Action on doshasHaritaki – Sarvadoshaprashamana; Amalaki – Tridoshajit; Bibhitaki – Kaphapittajit (API). AFI lists kaphapittaroga among the uses of Triphala Churna.
Karma (actions)Haritaki: Rasayana, Cakshushya, Dipana, Anulomana, Hridya, Medhya (API), Amalaki: Tridoshajit, Vrishya, Rasayana, Cakshushya (API), Bibhitaki: Kaphapittajit, Bhedaka, Kriminashana, Cakshushya, Keshya, Kasahara (API), Triphala Churna important therapeutic uses (AFI 7:15): anaha, prameha, netra roga, kaphapittaroga, kushtha, mandagni, aruci, vishama jvara
Classical formulationsTriphala Churna (AFI Part I, 7:15; Bhavaprakasha, Haritakyadi varga 41), Triphala Guggulu (AFI Part I, 5:5; Sharngadhara Samhita, Madhyama khanda 7), Triphala Ghrita (AFI Part I, 6:14), Triphaladi Taila (AFI Part I, 8:21), Maha Triphaladya Ghrita (AFI Part I, 6:35), Triphala Kvatha Churna (AFI Part II, 4.9; Bhaishajya Ratnavali, Shotharogadhikara 64)
Dose in the APITriphala Churna: 3 to 6 g, anupana ghee, honey or warm water (AFI Part I, 7:15). Each single fruit: 3-6 g of the drug in powder form (API Part I Vol I monographs 4, 17, 31). Triphala Kvatha Churna (AFI Part II, 4.9): 10 to 50 g for decoction.

Profile as recorded in the official texts[1, 2, 3, 4, 5].

Chemistry

Key constituents

  • API constituents: Amalaki dried fruit – ascorbic acid and gallotannins; Bibhitaki – gallic acid, tannic acid and glycosides; Haritaki – tannins, anthraquinones and polyphenolic compounds.[2, 3, 4]
  • T. chebula fruits are reported to contain 30–40% tannins, including chebulic, chebulinic, neochebulinic and chebulagic acids, corilagin, gallic and ellagic acids and punicalagin; P. emblica fruit is high in ascorbic acid and ellagitannins (emblicanins A and B, punigluconin, pedunculagin); T. bellirica contains gallic and ellagic acids, β-sitosterol and fatty acids.[8]
  • Gallic acid, chebulagic acid and chebulinic acid have been used as RP-HPLC markers for Triphala Churna, and the method was applied to show variation between Triphala Churna preparations.[25]
  • One standardised Triphala formulation contained 4.30 ± 2.09 mg/g gallic acid by RP-HPLC.[23]
  • Triphala polyphenols such as chebulinic and ellagic acid can be converted by gut microbiota into metabolites including urolithins; reviewers propose this as one mechanism for its effects in the gut (mechanistic, not proven clinically).[7, 8]

Research

What human studies show

The bottom line

The most consistent human evidence is for Triphala as a mouthrinse: several RCTs and meta-analyses found plaque and gingivitis reductions broadly comparable to chlorhexidine, though trials are small, short and heterogeneous, and one pooled Triphala estimate was not statistically significant. Evidence for oral Triphala in constipation comes from small open-label or poorly described studies without placebo control, and results for cholesterol, blood glucose and weight are mixed, including a null placebo-controlled trial of a Guggulu-Triphala combination. Most other claimed effects rest on laboratory and animal data.

meta-analysisEvidence: moderate

Oral health – plaque and gingivitis (mouthrinse)

Systematic review and meta-analysis of 7 RCTs comparing Triphala mouthwash with chlorhexidine (CHX) in plaque-induced gingivitis; searches to April 2020; outcomes gingival index (GI) and plaque index (PI).

Authors concluded Triphala mouthwash improved gingival inflammatory parameters with clinical efficacy comparable to chlorhexidine.[9]

Limitations: Very high statistical heterogeneity (I² 91.8% for GI, 96.1% for PI); small, mostly Indian trials of short duration; comparator-only design (no placebo arm in the pooled comparison).

meta-analysisEvidence: moderate

Oral health – plaque and gingivitis in children

Systematic review and random-effects meta-analysis of 5 studies in children (searches 1980–April 2023) comparing Triphala with chlorhexidine mouthwash.

No significant difference between Triphala and chlorhexidine in reduction of plaque index or gingival index (p = 0.83 and 0.96).[10]

Limitations: Only 5 studies; equivalence was inferred from non-significant differences rather than a formal non-inferiority analysis.

meta-analysisEvidence: limited

Oral health – herbal plaque control agents (incl. Triphala)

Systematic review and meta-analysis of 41 RCTs of Ayurvedic/herbal plaque control agents in gingivitis (2004–2021; PROSPERO CRD42021274656), with a Triphala subgroup.

For the Triphala subgroup, the pooled plaque-index effect was SMD −0.65 (95% CI −1.32 to 0.03), i.e. the confidence interval crossed zero; authors described herbal agents as 'as good as control'.[11]

Limitations: Pooled estimate for Triphala was not statistically significant; mixed products and comparators.

RCTEvidence: moderate

Oral health – school-based mouthwash trial

1,431 children aged 8–12; Triphala mouthwash 0.6% (n=457) vs chlorhexidine 0.1% (n=440) vs distilled water (n=412); 9 months.

Plaque scores fell progressively with both Triphala and chlorhexidine and rose with water; gingival effects were similar between Triphala and chlorhexidine; no significant difference between the two mouthwashes.[12]

Limitations: Allocation and blinding details limited in abstract; single region; surrogate outcomes.

RCTEvidence: moderate

Oral health – gingivitis in adults

90 adults with chronic generalised gingivitis; placebo vs Triphala vs chlorhexidine mouthwash twice daily; outcomes at 7, 30 and 60 days.

Triphala and chlorhexidine both reduced plaque index, gingival index, OHI-S and microbial counts more than placebo, with no significant difference between Triphala and chlorhexidine.[13]

Limitations: Single centre, 60 days, modest sample.

RCTEvidence: limited

Constipation

Open randomised controlled trial, 80 adults with chronic constipation (40 per arm; 34 and 38 completed); Triphala Churna 3–6 g at night with lukewarm water vs a prescribed Ayurvedic diet module; 4 weeks; National Institute of Ayurveda, Jaipur (CTRI/2019/09/021411).

Both groups improved significantly from baseline on bowel parameters; the diet group had greater improvement in weekly bowel frequency and colic pain, and groups were otherwise similar. No adverse effects reported.[14]

Limitations: Open-label, no placebo arm, small sample, Triphala used as the active control rather than tested against placebo.

observationalEvidence: preliminary

Constipation and digestive complaints

Clinical study, 160 patients aged 16–52 given an HPTLC-standardised Triphala formulation for 45 days (randomisation and control procedures not described in the abstract).

Stool amount, frequency and consistency improved in the Triphala group, along with reported reductions in flatulence, abdominal pain and hyperacidity; no adverse effects observed.[15]

Limitations: Design details unclear from available record; subjective scoring; published in a small journal; not placebo-controlled as far as can be seen.

observationalEvidence: preliminary

Functional constipation (Triphala-containing combination)

Open-label single-arm study, 34 patients, 14 days, proprietary powder containing isabgol husk, senna extract and Triphala extract.

Weekly bowel movements rose from 10.19 to 18.29, and stool form and straining improved; well tolerated.[16]

Limitations: No control group; product also contained senna and psyllium, so effects cannot be attributed to Triphala.

RCTEvidence: preliminary

Gut microbiota

Double-blind, placebo-controlled pilot; 31 healthy adults randomised to Triphala, manjistha or placebo 2,000 mg/day for 4 weeks; 16S rRNA profiling (Triphala n=9 completers).

Responses were highly individual and no taxa were uniformly altered; trends toward lower Firmicutes:Bacteroidetes ratio, more Akkermansia muciniphila and reduced Rikenellaceae with herb supplementation.[17]

Limitations: Very small pilot; microbiome surrogate outcomes only; no clinical endpoints.

systematic reviewEvidence: limited

Lipids, blood glucose and body weight

Systematic review of 12 RCTs (749 participants) of Triphala on lipid profile, blood glucose and anthropometric measures.

Six studies reported reductions in LDL-C, total cholesterol and triglycerides; five reported reductions in body weight, BMI and waist circumference in obese patients; fasting glucose fell in diabetic patients but not in people without diabetes. Authors call for large well-designed RCTs.[19]

Limitations: No meta-analysis; heterogeneous products and doses; small trials.

RCTEvidence: limited

Hypercholesterolaemia (null result)

Double-blind placebo-controlled RCT, 90 adults at low–moderate cardiovascular risk, Guggulu + Triphala three times daily for 3 months, 3-month follow-up (Italy).

No better effect than placebo on total or LDL cholesterol, BMI or waist circumference (LDL fell ~4.8–4.9% in both arms).[18]

Limitations: Tested a combination with guggulu, not Triphala alone; short duration.

RCTEvidence: preliminary

Scalp seborrhoea (oral)

Patient- and assessor-blinded placebo-controlled trial, 80 completers aged 14–50; Triphala 1 g twice daily (standardised to gallic acid) vs wheat-flour placebo for 8 weeks (Iran).

Triphala group showed 25.34 points (95% CI 0.39–50.29; p=0.047) more improvement in Sebumeter scalp sebum scores and higher satisfaction than placebo.[20]

Limitations: Single trial; confidence interval wide and near the null.

Laboratory and animal studies

These studies explain possible mechanisms. They do not show the same effect in people.

in vitroEvidence: preliminary

Preclinical (antioxidant, anti-inflammatory, antimicrobial, anticancer)

Narrative reviews of cell and animal studies.

Laboratory and animal studies report antioxidant, anti-inflammatory, immunomodulating, antibacterial, antimutagenic, hypoglycaemic and chemoprotective activity, and gut-microbiota modulation.[7, 8]

Limitations: Cell and animal data; do not establish effects in people. One review notes literature 'does not provide any clear evidence' on Triphala's effect on the human digestive tract and that no trials had tested it in IBS.

Safety

Safety, interactions and regulation

  • A 4-week open-label phase I study in 20 healthy Thai volunteers taking 2,500 mg/day Triphala aqueous extract reported no serious adverse effects on clinical examination, haematology or blood chemistry.[21]
  • A systematic review of 12 RCTs (749 participants) found no serious adverse events attributed to Triphala; in a placebo-controlled trial of a Guggulu + Triphala combination, 2 of 46 participants (4.3%) developed a hypersensitivity rash versus none on placebo.[19, 18]
  • Health Canada's monograph advises asking a health care practitioner before use in pregnancy or breastfeeding, not using the laxative product with fever or undiagnosed gastrointestinal trouble, seeking advice if no laxative effect occurs within 7 days, and taking it a few hours apart from other medications or health products; non-laxative products must carry a statement that a laxative effect may occur.[6]
  • Pregnant and lactating women were excluded from the 2022 constipation RCT, so trial safety data in pregnancy are lacking.[14]
  • Herb–drug interaction signal (in vitro only): a standardised Triphala formulation inhibited CYP3A4 and CYP2D6 in vitro (IC50 about 120 and 105 µg/ml) and rat liver microsomal CYP450 by 23%, less than positive controls; the authors flag implications for possible interactions, but clinical relevance is unknown.[23]
  • Animal toxicology: in Sprague-Dawley rats, a single 5,000 mg/kg oral dose showed no acute toxicity, and 600–2,400 mg/kg/day for 270 days produced no toxic effects on behaviour, organ weights or histopathology, though some blood chemistry and haematology values changed.[22]
  • Heavy metals: in a 2008 study, 20.7% of Ayurvedic products bought online (US- and Indian-made) contained detectable lead, mercury or arsenic, including 17.1% of non-rasashastra (herbal-only) products; this was not a Triphala-specific study, but it underlines the value of heavy-metal testing for any Ayurvedic product.[24]
  • Because Triphala has a laxative action (it is permitted in Canada as a traditional mild laxative), loose stools are an expected effect at higher intakes; Health Canada notes the mechanism is unclear and the effect is mild.[6]

Quality

Identity, standards and adulteration

  • Identity (API Part I Vol I): Amalaki – curled, grey-to-black pieces of dried pericarp, sour and astringent, stony testa removed; Bibhitaki – nearly spherical to ovoid fruit 2.5–4.0 cm, grey or greyish-brown, rind 3–5 mm, astringent; Haritaki – yellowish-brown ovoid fruit 20–35 mm long, longitudinally ribbed, fibrous pericarp 3–4 mm thick, non-adherent to the seed. API also gives microscopic characters for each.[2, 3, 4]
  • API limits – Amalaki (dried fruit): foreign matter (incl. seed and seed coat) ≤3%, total ash ≤7%, acid-insoluble ash ≤2%, alcohol-soluble extractive ≥40%, water-soluble extractive ≥50%. Bibhitaki: foreign matter ≤2%, total ash ≤7%, acid-insoluble ash ≤1%, alcohol-soluble extractive ≥8%, water-soluble extractive ≥35%. Haritaki: foreign matter ≤1%, total ash ≤5%, acid-insoluble ash ≤5%, alcohol-soluble extractive ≥40%, water-soluble extractive ≥60%.[2, 3, 4]
  • API notes Haritaki synonym Vijaya with the caution 'Not Bhanga' (i.e. not to be confused with cannabis, also called Vijaya).[4]
  • Composition: AFI 7:15 specifies equal parts (1:1:1) of Haritaki, Bibhitaka and Amalaki pericarp; Health Canada restricts use of the name 'Triphala' to products containing all three ingredients.[1, 6]
  • Chemical standardisation: RP-HPLC using gallic, chebulagic and chebulinic acids as markers has been validated for Triphala Churna and detected variation between commercial-type preparations; gallic acid has also been used as an HPTLC/HPLC marker in clinical-trial material.[25, 15, 20]
  • Gaps: no pharmacopoeial monograph for Triphala Churna as a finished formulation was located in API Part II Vols I–II (it was not in their contents lists); quality control therefore rests on the three single-drug API monographs plus in-house markers.

Manufacturing

How Triphala is made into medicines

In India Triphala is most often made as a churna (fine powder of equal parts of the three dried fruit pericarps, seed removed, AFI 7:15), and also appears as tablets, capsules and aqueous or hydro-alcoholic extracts (clinical trials have used aqueous-extract capsules and gallic-acid-standardised powder). Classical derived forms include Triphala Kvatha Churna (coarse powder for decoction, AFI Part II 4.9), Triphala Guggulu (powders pounded into purified guggulu, AFI 5:5), Triphala Ghrita (AFI 6:14) and Triphaladi Taila (AFI 8:21). Triphala decoction (Vara/Triphala kvatha) is also used in AFI as a processing liquid, for example in the amritikarana step for lauha bhasma. Mouthrinses used in dental trials were prepared at concentrations such as 0.6%.[1, 5, 21, 20, 12]

Prabhat makes churnas, tablets, capsules, kwaths, syrups and oils under AYUSH GMP for brands across India. See churna, tablet and capsule manufacturing, or white label products.

FAQ

Common questions about Triphala

What is Triphala made of?

Triphala Churna is equal parts of the dried fruit rind of Haritaki (Terminalia chebula), Bibhitaki (Terminalia bellirica) and Amalaki (Phyllanthus emblica, amla), as specified in the Ayurvedic Formulary of India citing the Bhavaprakasha. The seed is removed and the pericarp is powdered. In Canada, only products containing all three fruits may use the name 'Triphala'.[1, 2, 6]

Does Triphala help with constipation?

Triphala is traditionally used as a mild laxative, and Health Canada permits that traditional claim for occasional constipation. Small human studies have reported improved stool frequency and consistency, but they were open-label, lacked placebo control or were poorly described, so the evidence is limited. In one randomised trial, Triphala Churna and a prescribed diet both improved constipation over 4 weeks.[6, 14, 15]

Can Triphala be used as a mouthwash?

Triphala mouthrinses have been studied the most of any use: randomised trials in children and adults found reductions in plaque and gingivitis broadly similar to chlorhexidine. Meta-analyses support this but note small trials and high heterogeneity, and one pooled Triphala estimate was not statistically significant.[9, 10, 11, 13]

What are the side effects of Triphala?

In short human studies, including a 4-week trial at 2.5 g/day extract in healthy volunteers, no serious adverse effects were reported. Loose stools can occur because of its laxative action, and a rash was reported in 2 of 46 people taking a Guggulu-Triphala combination. Laboratory work suggests it may affect drug-metabolising enzymes, so Health Canada advises taking it a few hours apart from other medicines.[21, 6, 18, 23]

Can Triphala be taken during pregnancy?

There is little trial data in pregnancy; pregnant and breastfeeding women are usually excluded from Triphala studies. Health Canada advises asking a health care practitioner before use if pregnant or breastfeeding.[6, 14]

Does Triphala help with weight loss or cholesterol?

A systematic review of 12 small trials reported reductions in cholesterol, triglycerides and body weight in some studies, but the authors said larger well-designed trials are needed. A placebo-controlled trial of Guggulu plus Triphala for 3 months found no benefit over placebo on cholesterol, BMI or waist size.[19, 18]

References

Sources

  1. Government of India, Ministry of Health and Family Welfare, Department of ISM&H. The Ayurvedic Formulary of India, Part I, 2nd revised English edition. 2003. Formulation 7:15 Triphala Curna (citing Bhavaprakasa, Haritakyadi varga 41); also 5:5 Triphala Guggulu, 6:14 Triphala Ghrta, 8:21 Triphaladi Taila. Source.
  2. Government of India, Department of AYUSH. The Ayurvedic Pharmacopoeia of India, Part I, Volume I. Monograph 4: Amalaki (dried fruit), Emblica officinalis Gaertn. (syn. Phyllanthus emblica Linn.). Source.
  3. Government of India, Department of AYUSH. The Ayurvedic Pharmacopoeia of India, Part I, Volume I. Monograph 17: Bibhitaka (fruit), Terminalia belerica Roxb. Source.
  4. Government of India, Department of AYUSH. The Ayurvedic Pharmacopoeia of India, Part I, Volume I. Monograph 31: Haritaki (fruit), Terminalia chebula Retz. Source.
  5. Government of India, Ministry of Health and Family Welfare, Department of ISM&H. The Ayurvedic Formulary of India, Part II, 1st English edition. 2000. Formulation 4.9 Triphala Kvatha Curna (Shotharoga), citing Bhaisajyaratnavali, Sotharogadhikara 64. Source.
  6. Health Canada, Natural and Non-prescription Health Products Directorate. Natural Health Product Monograph: Triphala. Dated 29 November 2024. Source.
  7. Peterson CT, Denniston K, Chopra D. Therapeutic Uses of Triphala in Ayurvedic Medicine. J Altern Complement Med. 2017;23(8):607-614. PMID: 28696777. doi: 10.1089/acm.2017.0083.
  8. Tarasiuk A, Mosińska P, Fichna J. Triphala: current applications and new perspectives on the treatment of functional gastrointestinal disorders. Chin Med. 2018;13:39. PMID: 30034512. doi: 10.1186/s13020-018-0197-6.
  9. AlJameel AH, Almalki SA. Effect of triphala mouthrinse on plaque and gingival inflammation: A systematic review and meta-analysis of randomized controlled trials. Int J Dent Hyg. 2020;18(4):344-351. PMID: 32383334. doi: 10.1111/idh.12444.
  10. Minervini G, Marrapodi MM, Tirupathi S, Afnan L, Di Blasio M, Cervino G, Isola G, Cicciù M. Comparative anti-plaque and anti-gingivitis efficiency of Triphala versus chlorhexidine mouthwashes in children: a systematic review and meta-analysis. J Clin Pediatr Dent. 2024;48(5):51-59. PMID: 39275820. doi: 10.22514/jocpd.2024.103.
  11. Javed D, Dixit AK, Anwar S, Rai A, Krishan K. Ayurvedic and herbal plaque control agents in gingivitis: A systematic review and meta-analysis of randomized controlled trials. J Educ Health Promot. 2023;12:378. PMID: 38144032. doi: 10.4103/jehp.jehp_204_23.
  12. Bajaj N, Tandon S. The effect of Triphala and Chlorhexidine mouthwash on dental plaque, gingival inflammation, and microbial growth. Int J Ayurveda Res. 2011;2(1):29-36. PMID: 21897640. doi: 10.4103/0974-7788.83188.
  13. Pradeep AR, Suke DK, Martande SS, Singh SP, Nagpal K, Naik SB. Triphala, a New Herbal Mouthwash for the Treatment of Gingivitis: A Randomized Controlled Clinical Trial. J Periodontol. 2016;87(11):1352-1359. PMID: 27442086. doi: 10.1902/jop.2016.130406.
  14. Saini P, Agrawal SK. A Randomized Controlled Trial to Evaluate the Laxative Effect of Prescribed Diet Compared with Triphala Churna in Vibandha with Special Reference to Constipation. Journal of Ayurveda. 2022;16(2):106-111. doi: 10.4103/joa.joa_163_20.
  15. Mukherjee PK, Rai S, Bhattacharyya S, Debnath PK, Biswas TK, Jana U, Pandit S, Saha BP, Paul PK. Clinical Study of 'Triphala' – A Well Known Phytomedicine from India. Iranian Journal of Pharmacology and Therapeutics. 2007;5(1):51-54. Source.
  16. Munshi R, Bhalerao S, Rathi P, Kuber VV, Nipanikar SU, Kadbhane KP. An open-label, prospective clinical study to evaluate the efficacy and safety of TLPL/AY/01/2008 in the management of functional constipation. J Ayurveda Integr Med. 2011;2(3):144-152. PMID: 22022157. doi: 10.4103/0975-9476.85554.
  17. Peterson CT, Pourang A, Dhaliwal S, Kohn JN, Uchitel S, Singh H, Mills PJ, Peterson SN, Sivamani RK. Modulatory Effects of Triphala and Manjistha Dietary Supplementation on Human Gut Microbiota: A Double-Blind, Randomized, Placebo-Controlled Pilot Study. J Altern Complement Med. 2020;26(11):1015-1024. PMID: 32955913. doi: 10.1089/acm.2020.0148.
  18. Donato F, Raffetti E, Toninelli G, Festa A, Scarcella C, Castellano M, TRIGU Project Working Group. Guggulu and Triphala for the Treatment of Hypercholesterolaemia: A Placebo-Controlled, Double-Blind, Randomised Trial. Complement Med Res. 2021;28(3):216-225. PMID: 33242870. doi: 10.1159/000510985.
  19. Phimarn W, Sungthong B, Itabe H. Effects of Triphala on Lipid and Glucose Profiles and Anthropometric Parameters: A Systematic Review. J Evid Based Integr Med. 2021;26:2515690X211011038. PMID: 33886393. doi: 10.1177/2515690X211011038.
  20. Zareie E, Mansouri P, Hosseini H, Sadeghpour O, Shirbeigi L, Hejazi S, Emtiazy M. Effect of oral administration of Triphala, a polyphenol-rich prebiotic, on scalp sebum in patients with scalp seborrhea a randomized clinical trial. J Dermatolog Treat. 2022;33(2):1011-1016. PMID: 32698634. doi: 10.1080/09546634.2020.1800568.
  21. Phetkate P, Kummalue T, Rinthong PO, Kietinun S, Sriyakul K. Study of the safety of oral Triphala aqueous extract on healthy volunteers. J Integr Med. 2020;18(1):35-40. PMID: 31680053. doi: 10.1016/j.joim.2019.10.002.
  22. Arpornchayanon W, Subhawa S, Jaijoy K, Lertprasertsuk N, Soonthornchareonnon N, Sireeratawong S. Safety of the Oral Triphala Recipe from Acute and Chronic Toxicity Tests in Sprague-Dawley Rats. Toxics. 2022;10(9):514. PMID: 36136479. doi: 10.3390/toxics10090514.
  23. Ponnusankar S, Pandit S, Babu R, Bandyopadhyay A, Mukherjee PK. Cytochrome P450 inhibitory potential of Triphala--a Rasayana from Ayurveda. J Ethnopharmacol. 2011;133(1):120-125. PMID: 20883765. doi: 10.1016/j.jep.2010.09.022.
  24. Saper RB, Phillips RS, Sehgal A, Khouri N, Davis RB, Paquin J, Thuppil V, Kales SN. Lead, mercury, and arsenic in US- and Indian-manufactured Ayurvedic medicines sold via the Internet. JAMA. 2008;300(8):915-923. PMID: 18728265. doi: 10.1001/jama.300.8.915.
  25. Pawar V, Lahorkar P, Anantha Narayana DB. Development of a RP-HPLC Method for Analysis of Triphala Curna and its Applicability to Test Variations in Triphala Curna Preparations. Indian J Pharm Sci. 2009;71(4):382-386. PMID: 20502543. doi: 10.4103/0250-474X.57286.

How this page was written. Every statement links to a source we opened. PubMed IDs were checked against the NCBI database. Human studies are kept apart from laboratory and animal work, and null results are included. Read our method.

Author: Aashish Passi, Managing Director, Prabhat Ayurvedic Pharmacy. Last updated: 16 October 2026. Spotted an error? Email info@prabhatayurvedicpharmacy.in.

This page is educational and summarises published research. It is not medical advice and is not a claim for any product. Talk to a qualified doctor before using any herbal medicine, especially if you are pregnant, breastfeeding, taking medicines or have a medical condition.

More in the herb library: